STING1 and neoplasm: Researchers have proposed using STING inhibitors to suppress the development of CIN tumors, a strategy that has been validated in mice.12 However, an intriguing idea is whether the combined use of STING agonists and ER stress response inhibitors could redirect the downstream pathway towards the production of type I IFN, thereby leveraging the anti-tumor effect of the STING pathway.